source
- Sanofi pays Regeneron $1 billion upfront to co-develop four early-stage immunology assetsSanofi has agreed to pay Regeneron an upfront fee of $1 billion to partner on four early‑stage immunology programs, a move intended to capture the success of their joint Dupixent antibody. Dupixen…
- Eli Lilly, Novo, AbbVie and Boehringer showcase new obesity drug data at European meetingThe European Association for the Study of Diabetes held its annual meeting in Milan, drawing obesity and metabolic disease experts and providing a platform for drugmakers to present emerging weight…